Trends in Prescribing of Antibiotics and Drugs Investigated for Coronavirus Disease 2019 (COVID-19) Treatment in US Nursing Home Residents During the COVID-19 Pandemic

被引:22
作者
Gouin, Katryna A. [1 ]
Creasy, Stephen [2 ]
Beckerson, Mary [2 ]
Wdowicki, Martha [2 ]
Hicks, Lauri A. [3 ]
Lind, Jennifer N. [4 ]
Geller, Andrew, I [4 ]
Budnitz, Daniel S. [4 ]
Kabbani, Sarah [3 ]
机构
[1] US Ctr Dis Control & Prevent, Chenega Corp, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA
[2] PharMerica, Louisville, KY USA
[3] US Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA
[4] US Ctr Dis Control & Prevent, CDC COVID 19 Response, Atlanta, GA USA
关键词
nursing home; antibiotic stewardship; adverse drug events; COVID-19; ANTIMICROBIAL USE; UNITED-STATES; HYDROXYCHLOROQUINE; POLYPHARMACY; THERAPY;
D O I
10.1093/cid/ciab225
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Trends in prescribing for nursing home (NH) residents, which may have been influenced by the coronavirus disease 2019 (COVID-19) pandemic, have not been characterized. Methods Long-term care pharmacy data from 1944 US NHs were used to evaluate trends in prescribing of antibiotics and drugs that were investigated for COVID-19 treatment, including hydroxychloroquine, famotidine, and dexamethasone. To account for seasonal variability in antibiotic prescribing and decreased NH occupancy during the pandemic, monthly prevalence of residents with a prescription dispensed per 1000 residents serviced was calculated from January to October and compared as relative percent change from 2019 to 2020. Results In April 2020, prescribing was significantly higher in NHs for drugs investigated for COVID-19 treatment than 2019; including hydroxychloroquine (+563%, 95% confidence interval [CI]: 5.87, 7.48) and azithromycin (+150%, 95% CI: 2.37, 2.63). Ceftriaxone prescribing also increased (+43%, 95% CI: 1.34, 1.54). Prescribing of dexamethasone was 36% lower in April (95% CI: .55, .73) and 303% higher in July (95% CI: 3.66, 4.45). Although azithromycin and ceftriaxone prescribing increased, total antibiotic prescribing among residents was lower from May (-5%, 95% CI: .94, .97) through October (-4%, 95% CI: .94, .97) in 2020 compared to 2019. Conclusions During the pandemic, large numbers of residents were prescribed drugs investigated for COVID-19 treatment, and an increase in prescribing of antibiotics commonly used for respiratory infections was observed. Prescribing of these drugs may increase the risk of adverse events, without providing clear benefits. Surveillance of NH prescribing practices is critical to evaluate concordance with guideline-recommended therapy and improve resident safety. During the coronavirus disease 2019 (COVID-19) pandemic, there was a higher prevalence of nursing home residents with a prescription dispensed for drugs that were investigated for COVID-19 treatment and antibiotics commonly used for respiratory infections than in the previous year.
引用
收藏
页码:74 / 82
页数:9
相关论文
共 31 条
[1]  
[Anonymous], 2010, FDA drug safety communication: Safety update for osteoporosis drugs, bisphosphonates, and atypical fractures
[2]  
Borrell B., 2020, SCIENCE, DOI 10.1126/science.abc4739
[3]   Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment - United States, January-June 2020 [J].
Bull-Otterson, Lara ;
Gray, Elizabeth B. ;
Budnitz, Daniel S. ;
Strosnider, Heather M. ;
Schieber, Lyna Z. ;
Courtney, Joseph ;
Garcia, Macarena C. ;
Brooks, John T. ;
Mac Kenzie, William R. ;
Gundlapalli, Adi, V .
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2020, 69 (35) :1210-1215
[4]   Symptom Profiles of a Convenience Sample of Patients with COVID-19-United States, January-April 2020 [J].
Burke, Rachel M. ;
Killerby, Marie E. ;
Newton, Suzanne ;
Ashworth, Candace E. ;
Berns, Abby L. ;
Brennan, Skyler ;
Bressler, Jonathan M. ;
Bye, Erica ;
Crawford, Richard ;
Morano, Laurel Harduar ;
Lewis, Nathaniel M. ;
Markus, Tiffanie M. ;
Read, Jennifer S. ;
Rissman, Tamara ;
Taylor, Joanne ;
Tate, Jacqueline E. ;
Midgley, Claire M. .
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2020, 69 (28) :904-908
[5]   The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro [J].
Caly, Leon ;
Druce, Julian D. ;
Catton, Mike G. ;
Jans, David A. ;
Wagstaff, Kylie M. .
ANTIVIRAL RESEARCH, 2020, 178
[6]  
Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI [10.1056/NEJMoa2001282, 10.1056/NEJMc2008043]
[7]   Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients [J].
Carlucci, Philip M. ;
Ahuja, Tania ;
Petrilli, Christopher ;
Rajagopalan, Harish ;
Jones, Simon ;
Rahimian, Joseph .
JOURNAL OF MEDICAL MICROBIOLOGY, 2020, 69 (10) :1228-1234
[8]   The impact of drug interactions and polypharmacy on antimicrobial therapy in the elderly [J].
Corsonello, A. ;
Abbatecola, A. M. ;
Fusco, S. ;
Luciani, F. ;
Marino, A. ;
Catalano, S. ;
Maggio, M. G. ;
Lattanzio, F. .
CLINICAL MICROBIOLOGY AND INFECTION, 2015, 21 (01) :20-26
[9]   Polypharmacy in Nursing Home Residents in the United States: Results of the 2004 National Nursing Home Survey [J].
Dwyer, Lisa L. ;
Han, Beth ;
Woodwell, David A. ;
Rechtsteiner, Elizabeth A. .
AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY, 2010, 8 (01) :63-72
[10]  
Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI [10.1016/j.ijantimicag.2020.105949, 10.1016/j.ijantimicag.2020.106063]